DiaMedica Therapeutics's book value per share for the quarter that ended in Mar. 2026 was $0.88.
During the past 12 months, DiaMedica Therapeutics's average Book Value Per Share Growth Rate was 10.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -4.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -8.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of DiaMedica Therapeutics was 123.10% per year. The lowest was -50.70% per year. And the median was -2.65% per year.
During the past 13 years, the highest P/B Ratio of DiaMedica Therapeutics was 51.46. The lowest was 1.16. And the median was 3.87.
DiaMedica Therapeutics (NAS:DMAC) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
DiaMedica Therapeutics Book Value per Share Related Terms
DiaMedica Therapeutics Book Value per Share Historical Data
* Premium members only.
The historical data trend for DiaMedica Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMAC vs PRLD, RCKT, TENX: Book Value per Share Comparison
For the Biotechnology subindustry, DiaMedica Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics (DMAC) has a Book Value per Share of $0.88 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Book Value per Share too high?
DiaMedica Therapeutics' current Book Value per Share is $0.88. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Book Value per Share compare to PRLD and RCKT?
DiaMedica Therapeutics' Book Value per Share of $0.88 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Book Value per Share is $0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Book Value per Share of $0.88. The current Book Value per Share is $0.88. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Book Value per Share is $0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score
Get the complete analysis for DMAC
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 
